ReviewFrontiers in immunology2025
Advances in understanding the role of pentraxin-3 in lung infections.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Diagnostic value of pentraxin 3 in plasma and bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in non-neutropenic patients: a prospective multicenter clinical study.Emerging microbes & infections · 2026Article
- Impact of Exercise Modalities on Pentraxin-3 (PTX3) Levels: A Systematic Review and Meta-Analysis.Muscles (Basel, Switzerland) · 2025Review
- Impaired Efferocytosis of Pericytes and Vascular Smooth Muscle Cells in Diabetic Retinopathy.Cells · 2025Review
- Immune markers for pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a narrative review.Frontiers in immunology · 2025Review
- Exploring the structural basis and functional immunodynamics of immunoglobulin M in host defense against fungal pathogens.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pentraxin-3 (PTX3) is a soluble pattern recognition molecule (PRM) characterized by a C-terminal pentraxin structural domain and a unique N-terminal structural domain. As a key component of the innate immune system, PTX3 can be rapidly released into the extracellular space during microbial invasion and inflammatory responses. It plays a crucial role in regulating complement activation, enhancing the ability of myeloid cells to recognize pathogens, and exerting various immune effects. PTX3 is integral to the regulation of innate immunity, inflammation, and tumor dynamics through its dual function as both a pro-inflammatory and anti-inflammatory mediator depending on the context. This role is closely linked to its diverse molecular and cellular targets. Additionally, PTX3 has been implicated in the pathogenesis of various lung diseases through its involvement in numerous physiological and pathological processes. In this paper, we summarize the complex immunological functions of PTX3 and review the multifaceted roles it plays in the development of infectious lung diseases. Our objective is to highlight the potential for clinical targeting of PTX3 as a biomarker in infectious diseases and to propose it as a viable alternative in future therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.